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doi:10.1016/j.jmii.2011.01.003Background: The incidence of invasive Group B streptococcal (GBS) infections is increasing in
the elderly and immunocompromised adults in many countries worldwide. There are, however,
few reports regarding the current status of the infection in northern Taiwan. This study inves-
tigated retrospectively the molecular epidemiology and clinical syndromes of the invasive GBS
diseases in a tertiary care hospital in northern Taiwan over the past decade.
Methods: One hundred twenty episodes of invasive GBS disease were recorded at Cathay
General Hospital, a tertiary care, teaching hospital in northern Taiwan, from January 1998
to June 2009. Clinical information was acquired from medical records. Capsular serotypes
and alpha family of surface proteins were genotyped with multiplex and specific polymerase
chain reaction.
Results: Of all episodes, 58.3% was found in the elderly (age 65), 36.1% in nonpregnant
women and young adults (age 18e64), and 5.9% in the neonates (0e90 days). Case-fatality rate
was 6.7%. Eighty-three (69%) of the invasive isolates were available for genotyping. In sharp
contrast to the studies in southern Taiwan (1991e2004), Type Ib (26.5%) was the most frequent
invasive isolate, followed by V (22.9%), III (18.1%), VI (12%), Ia (10.8%), II (6%), VIII (2.4%), and
nontypable strain (1.2%). In particular, Serotype VI, which had been rarely implicated in inva-
sive infection, emerged as a significant pathogen. A significant trend of increase in incidenceof Internal Medicine, Cathay General Hospital, 280 Ren-Ai Road, Section 4, Da-an District, Taipei City
.tw (C.H. Huang).
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Serotypes, surface proteins, and clinical syndromes of invasive Group B 9was observed for the infection (p< 0.0001), with concurrent increase of cases in the elderly
and of Serotype Ib and VI. There was significant association with young adults of Type II and
III and chronic skin conditions and older adults with Type Ia and V and chronic cardiovascular
diseases. Type V was closely associated with skin and soft tissue infection. Recurrent episodes
(10%) occurred most often in patients with concomitant malignancy, with an average of 314
days for recurrence.
Conclusions: The incidence of GBS invasive infection among nonpregnant women and adults is
rising in northern Taiwan, particularly in the elderly caused by Serotype Ib and VI. Population-
based surveillance program should be implanted for assessment of the disease burden to the
susceptible adult population.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Group B streptococci (GBS), or referred to as Streptococcus
agalactiae, is the leading cause of neonatal pneumonia,
septicemia, and meningitis and responsible for significant
morbidity of vulnerable adult populations. Commonly
colonized along the genitourinary tracts, the pathogens
either gain access to the fetus by transcending across
placenta and infecting amniotic fluid and fetus alike, or to
a lesser extent, are acquired during vaginal delivery after
aspiration of contaminated vaginal secretions. As a result of
perinatal antimicrobial prophylaxis, a significant trend
towards reduction in the incidence of neonatal GBS sepsis
was seen over the past decade.1 Consequently, the burden
of invasive GBS diseases has gradually shifted to adult
population, in particular those older with chronic under-
lying diseases.1
Multiple factors in the host and GBS have been shown to
contribute to the development of systemic infection.
Comorbidity, such as chronic cardiac disease/congestive
heart failure, diabetes mellitus (DM), malignancy, gastro-
intestinal and liver diseases, and bedridden or residence in
a nursing home were among those commonly seen in
patients with invasive GBS infection.2 For the pathogen, the
antiphagocytic capsules around the cocci are one of the
most important virulence factors contributing to the inva-
siveness. At least nine different serotypes are identified,
that is, Ia, Ib, and IIeVIII; among them, Type III predomi-
nates among the neonatal infection,3 of which a recently
identified surface serine-rich repeat protein (Srr-2) was
implicated in the high virulence of the serotype.4 In
contrast to the neonatal infection, specific virulence
inherent in the polysaccharide capsule that distinguishes
invasive serotypes from colonizers in the adult population
remains largely unknown. Nevertheless, the capsular sero-
type distribution of invasive strains is not uniform and
reflects the frequency of colonizing strains, which further is
subject to geographical as well as temporal variation.5
From the perspective of vaccination, it is important to
institute programs for continual, population-based surveil-
lance of GBS infection to include appropriate capsular
polysaccharide (CPS) in vaccine.
The aim of the present study was to analyze GBS invasive
infection retrospectively of the patients admitted to our
hospital during the past decade (1998e2009). By comparingour results with those from southern Taiwan (1991e2004),6,7
we would see the trend of the systemic infection by GBS in
Taiwan and possible clinical implication for themanagement
of the infected patients.Methods
Study population and definitions
Cathay General Hospital, an 800-bed, tertiary care,
teaching hospital in northern Taiwan, has averaged 27,000
patients admission per year. From January 1998 to January
2009, 120 episodes of invasive GBS infections, defined as
infection accompanied by isolation of the bacteria from
blood or cerebrovascular fluid, were identified from labo-
ratory records. Infection by GBS isolated within 2 weeks
from the same patient was arbitrarily defined as one
episode and were considered separate if occurred 2 weeks
apart. Clinical information, including patients’ demo-
graphic data, clinical syndromes, comorbid diseases,
underlying conditions, antimicrobial therapy and treatment
duration, and mortality, were obtained directly from
medical records. Death was attributed to the infection
if the affected patient died within 7 days after the first
day of culture-proved GBS infection. Cases were classified
as early-onset (0e13 days) or late-onset (14e90 days)
neonatal diseases, younger adult without pregnancy
( 18e64 years), and elderly ( 65 years). Although preg-
nant women with GBS infection are important subjects to
study, there was no invasive GBS disease found in pregnant
women during this study period.
GBS strains
The GBS strains preserved at 80C were recovered by
resuspension of frozen stocks in Brain-Heart infusion broth
and plating on 5% sheep blood agar, which were then
incubated for 24 hours. Recovered strains were confirmed
as GBS by Gram stain (positive cocci in chains), narrow zone
of beta hemolysis, negative catalase, positive CAMP test,
and the presence of Group B Lancefield antigen. Anti-
microbial susceptibility for penicillin, vancomycin, and
erythromycin was assessed by using the Kirby-Bauer disc
diffusion test, according to standards by CLSI M100-S19.
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of surface proteins
The CPS serotypes of the recovered GBS strains were
characterized by genotyping of CPS synthesis gene clusters
(cps) with polymerase chain reactions (PCRs) as described
previously.8,9 In brief, GBS serotypes were first identified
with PCR-based restriction fragment length polymorphism
(PCR-RFLP) using primers flanking cpsG and cpsL for Sero-
type Ia, Ib, IIeVII and cpsR to cpsL for Type VIII.8 Serotypes
characterized in this way were reconfirmed with a pair of
primers unique for each serotypes.9 Genes for alpha family
of surface proteins, including bca, epsilon/alpha1, alpha2,
alpha3, alpha4, and rib were identified as described.10,11
Statistical analysis
Data were collected and analyzed using Windows Office
Excel and SPSS software version 16 (SPSS Inc., Chicago, IL,
USA). Changes in incidence over time were analyzed by chi-
squared test for trend. Correlations between nominal
variables were assessed for significance by chi-squared test
or Fisher’s exact test. A p value of 0.05 or less was
considered statistically significant.
Result
During the period of January 1998 to June 2009, 108
patients with 120 episodes of invasive GBS disease were
recorded. Seventy (58.3%), 43(36.1%), and 7(5.9%) of theseTable 1 Distribution of clinical syndromes and comorbidity amon
and older adults ( 65 years)
Neonates (nZ 7)
Sex, male/female 5/2
Clinical syndrome
Primary bacteremia 1
SSTI 0
Osteomyelitis/septic arthritis 0
Pneumonia 3
UTI 1
Meningitis 2
Others 0
Comorbidity
DM
Cardiac disease
Renal disease
Liver disease
Skin condition
Malignancy
COPD
CVA
a p< 0.05.
b p< 0.005.
COPDZ chronic obstructive pulmonary disease; CVAZ cerebrovascu
infection; UTIZ urinary tract infection.episodes were found in the elderly ( 65 years old, range
65e93 years old), nonpregnant women and young adults
(< 65 years old, range 22e64 years old), and the neonates
(0e90 days, range 1e33 days), respectively. None of the
patients were found between ages 3 months to 18 years.
Female patients seemed, yet statistically insignificant,
more prevalent in the elderly group than in the young
adults group (57.8% vs. 41.2%, pZ 0.12) (Table 1).
The incidence of invasive GBS diseases increased from
0.2 episodes per 1,000 admissions in 1998 to 0.9 episodes
per 1,000 admissions in 2008 (p< 0.0001) (Fig. 1). Similarly,
the percentage of GBS isolated from cases of positive blood
culture also increased from 0.46% in 1998 to 1.40% in 2008
(p< 0.0001). Among three groups, only in the elderly group
the incidence rate increased over time (p< 0.01) (Fig. 1).
Eight of the 120 invasive GBS episodes were fatal,
accounting for a mortality rate of 6.7%. All GBS in these 120
episodes were susceptible to penicillin and vancomycin,
and 47% were resistant to erythromycin.
Neonates and infants
Of the seven neonates with invasive GBS diseases, four
(57%) cases were early onset (< 7 days after birth) and
three (43%) were late onset (7e90 days after birth).
Pneumonia was the most common manifestation (3, 43%),
followed by meningitis (2, 28%), urosepsis (1, 14%) and
bacteremia without identified source/primary bacteremia
(1, 14%). All early-onset cases symptoms developed within 1
day, with the majority being of pneumonia (3, 75%). There
was one preterm neonate with early-onset disease ofg infants, nonpregnant women and young adults (< 65 years),
Adults < 65 yr (nZ 43) Adults  65 yr (nZ 70)
25/18 29/41
12 16
19 27
4 8
1 2
3 7
0 0
4 10
12 19
8 28a
4 7
5 6
7b 0
11 20
1 4
1 9
lar accident; DMZ diabetes mellitus; SSTIZ skin and soft tissue
Figure 1. Incidence of invasive Group B streptococcal disease among infants (0e90 days), young adults (< 65 years), and older
adults ( 65 years).
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were identified, including two cases of meningitis, one
pneumonia, and one urosepsis. The mortality rate in the
neonatal group was 14.3% (1 term neonate with early-onset
disease).
Adults
One hundred thirteen cases were identified in adults of 18
years or older (range 22e93 years). There were no cases
identified of invasive GBS infections for pregnant women.
Most clinical manifestations were skin and soft tissue
infection (SSTI) (46, 40.7%), followed by primary bacter-
emia (28, 24.8%), osteomyelitis/septic arthritis (12, 10.6%),
urinary tract infection (10, 8.8%), endocarditis (4, 3.5%),
pneumonia (3, 2.7%), and polymicrobial bacteremia
following lower gastrointestinal surgery (2, 1.8%). No
association between clinical manifestations and age groups
was found. However, chronic skin diseases were found
predominant in the young adults group (18.4% vs. 0%,
pZ 0.001 by Fischer’s exact test), and patients in the
elderly group were more likely to have chronic cardiovas-
cular diseases (44.4% vs. 21.1%, pZ 0.017). Overall,
chronic cardiovascular diseases are the most commonly
associated comorbidity (35.6%) followed by malignancy and
DM (each 30.7%). Genitourinary (11, 35.5%) and breast
cancer (4, 12.9%) together account for nearly half of all
cases with malignancy, with the majority associated with
either SSTI (9/15) or urinary tract infection (2/15).Table 2 Distribution of Group B streptococcal capsular serotyp
Variable (n) Ia (%) Ib (%) II (%)
Primary bacteremia (nZ 18) 4 (22.2) 6 (33.3) 2 (11.1)
SSTI (nZ 28) 2 (7.1) 6 (21.4) 2 (7.1)
Osteomyelitis/septic
arthritis (nZ 9)
0 (0) 2 (22.2) 1 (11.1)
Pneumonia (nZ 6) 3 (50.0)a 0 (0) 0 (0)
UTI (nZ 9) 0 (0) 4 (44.4) 0 (0)
Meningitis (nZ 1) 0 (0) 1 (100) 0 (0)
a p< 0.05.
SSTIZ skin and soft tissue infection; UTIZ urinary tract infection.Serotypes and surface proteins
Of the 120 invasive episodes, 83 (69%) strains were recov-
erable for serotyping and surface protein characterization.
Two strains of each Serotype Ia, Ib, and III were isolated
from the neonates (86% recovery rate). The only fatal case
in this age group was caused by Serotype III.
Among adult patients, Serotype II (5/5, pZ 0.007) and
III (9/13, pZ 0.014) were closely associated with young
adults, whereas Serotype Ia (6/7, pZ 0.03) and VI (9/10,
pZ 0.078) were found chiefly in the elderly. With regard to
clinical syndromes, Type V is highly associated with SSTI
(10/18, 52.6%, pZ 0.047) (Table 2). Although Serotype VIII
were only isolated from patients with osteomyelitis (2/2,
pZ 0.01), the sheer case number precludes general
conclusion made to the serotype. Two serotypes (Ib and VI)
increased in incidence with time among annual positive
blood cultures (p< 0.001 and pZ 0.012, respectively). In
particular, the two serotypes together accounted for nearly
half of all recoverable isolated strains each year (Fig. 2),
suggesting the trend for invasive GBS infection was attrib-
utable for most part to the emergence of these two specific
serotypes.
To gain further insights into the population structure of
the invasive GBS strains, we characterized bacterial surface
proteins of the Alp family, which were encoded by bca,
alpha1/epsilon, alpha2, alpha3, alpha4, and rib genes. It
has been shown that the Alp family proteins are capable of
eliciting host protective antibodies; therefore, informationes by clinical syndromes
III (%) V (%) VI (%) VIII (%) NT (%)
3 (16.7) 3 (16.7) 0 (0) 0 (0) 0 (0)
4 (14.3) 10 (35.7)a 4 (14.3) 0 (0) 0 (0)
1 (11.1) 2 (22.2) 1 (11.1) 2 (22.2)a 0 (0)
2 (33.3) 1 (16.7) 0 (0) 0 (0) 0 (0)
3 (33.3) 2 (22.2) 0 (0) 0 (0) 0 (0)
0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Figure 2. Distribution of Group B streptococcal capsular serotypes by year. *Data was collected from January 2009 to June 2009
only.
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strains is as important as that for the immunogenic capsular
antigens in vaccine development. Most surface protein
genes in our isolates were bca (47%), followed by alpha3
(20%), rib (20%) and alpha1/epsilon (12%). Neither alpha2
nor alpha4 was found in our isolates. The rib gene was
found more frequently in young adults (pZ 0.006). Five
major serovariants, including Ib/bca (26.5%), V/alpha3
(18.1%), III/rib (14.5%), VI/bca (10.8%), and Ia/alpha1
(8.4%), represented 78.3% of all isolates. Because both
Serotypes Ib and VI are highly associated with the presence
of bca (22/22 and 9/10, respectively), a trend for bca to
increase with time was also observed (pZ 0.001).
Eighteen of the 120 episodes were distributed among six
patients who had total 12 recurrent invasive GBS diseases,
with average interval of 314 days (range 49e875 days) for
recurrence. Most of these patients (5/6, 83%) had malig-
nancy. In particular, four patients with recurrent infection
manifested SSTI for the first and subsequent recurrent
episodes. Among five strains recovered from the 12 recur-
rent episodes, 3 shared the same capsular serotype and
surface protein genes (i.e. same serovariants) with those
isolated from the antecedent infection. The intervals for
disease recurrence by these three strains were all less than
1 year (113, 337, and 347 days). In contrast, the other two
strains of different serovariants from their respective
predecessors were isolated more than 1 year away from
antecedent episodes (411 and 716 days).Discussion
Our study analyzing all GBS invasive infections in a medical
center from 1998 to 2009 revealed several important facts.
First, the incidence of the infection increased among
patients admitted for in-hospital care, and the trend is
mainly because of the increased frequency of the infection
in the elderly ( 65 years). Second, compared with the
results from studies in southern Taiwan (1991e2004),6,7 our
data demonstrated a dramatic increase in the frequency of
isolation of Serotype Ib and VI, both of which paralleled the
general trend of the invasive diseases and concurrent
decrease of Serotype III and Ia among the invasive isolates.
Third, comorbid conditions and strain serotypes were
distributed unevenly between young (< 65 years) and old( 65 years) adults. Chronic skin diseases and Serotype II
and III were found predominantly in the young adults, and
chronic cardiovascular diseases and Serotype Ia and VI were
found in the elderly. Fourth, Serotype V is closely associ-
ated with clinical manifestations of SSTI. Finally, recurrent
episodes of invasive infection often presented as SSTI in
patients with malignancy by strains of the same serovar-
iants as preceding ones.
Increases in the incidence of invasive GBS disease in
elderly adults have been observed worldwide, including
Spain (1985e1994),12 the United States (1999e2005),1 and
Norway (1996e2006),13 with up to fourfold increase over
two decades (review in Refs.2,14). The increase in disease
burden to the elderly may be a direct result of aging pop-
ulation with consequent immune senescence impairing cell-
mediated immunity. In addition, several known comorbid
conditions, which are predominantly associated with the
older adults, are conducive to the acquirement of the
infection as the population become older.2 Our retrospec-
tive analysis, albeit sampled from a medical center,
revealed comparable trend in the disease incidence and
characteristics of patients’ underlying conditions and clin-
ical manifestations. This suggests that the invasive infec-
tion caused by GBS is an increasing threat to the adult
population in Taiwan as are in other countries, especially to
the elderly with comorbid conditions, such as malignancy,
DM, cardiac, GI, and liver diseases.15
Prevalence of GBS capsular serotypes, on the other
hand, differs in several aspects from previous studies
in southern Taiwan (1991e2004).6,7 In contrast to the
predominance of Serotypes III and V, which together
accounted for more than 60% of all isolated strains in their
studies, Ib (26%) and V (24.7%) are the two most frequently
isolated strains in our study. This remarkable change in
serotype distribution may be explained in part by the fact
that most of our cases came from the adult population
(94%), as Serotype III is known to be dominant in the
neonatal cases.16 Differences in prevalence of serotypes
between geographically distinct areas, that is, south versus
north Taiwan, could lead to the discrepancy in serotype
distribution. Of all, increasing incidence of Type Ib (Fig. 2)
appeared to be the most important contributing factor.
Change in serotype distributions over time is not
uncommon. Persson et al.5 observed a twofold increase in
Serotype V from the period of 1988e1991 to 1998e2001 in
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age, with concurrent decrease in Serotype Ib for the adult
cases. Our result reinforces the importance of regional
dynamic change in serotype distribution, and timely active
surveillance is vital to formulating effective vaccines for
the population within the areas.
The emergence of Serotype VI, especially among those
isolated after year 2006, is alarming. Type VI in general is
not a common serotype of all CPS antigens. Prior study in
southern Taiwan between 1994 and 20047 showed only 2.6%
of Type VI in 156 strains. In sharp contrast, however,
Serotype VI, along with VIII, were overwhelmingly repre-
sented by vaginal colonizing strains isolated form healthy
pregnant Japanese women (24.7% and 35.6%, respec-
tively).17 Given the geographical proximity and prosperous
mutual tourism, the emerging of Type VI in our study may
reflect a direct spread of GBS from Japan to Taiwan.
Alternatively and more worrisome, such a change in sero-
type distribution beacons clonal expansion of virulent
strains carrying the capsular antigen. In support of this, 90%
(9/10) of all isolated Type VI carried the surface protein
gene bca, suggesting some degree of relatedness among
these strains. Further genome analysis of these strains to
delineate the extent of clonality, in relation to those from
Japan and Taiwan, should provide answers to these
questions.
The finding of Serotype V in association with SSTI is, to
our knowledge, the first report linking Type V to a specific
clinical syndrome. Except in the neonates, in whom Type III
is associated with neonatal late-onset meningitis,3,16,18
there have been few reports for adult patients describing
association of serotypes with particular syndromes. On the
other hand, different serotypes seem to vary in their
immunogenicity during naturally acquired subclinical
infection. For example, serotype-specific IgG against Type
VIII was at higher level in healthy colonized women than
those against Ia, Ib, II, and III.19 In contrast, the level of
Type V antibody in healthy colonized elderly persons was
the lowest among all measured type-specific antibodies.2
The variation in immunogenicity was not observed in
vaccinated volunteers, suggesting that different serotypes
may be equally potent to generate host adaptive immunity.
The ability to evade host innate immunity, however, may
not be equal among strains of different serotypes during
natural infection. Thus, Serotype V may be more suscep-
tible to macrophage bactericidal functions and thus prone
to localized inflammation, making it difficult to cause
systemic spread and effectively generate adaptive antibody
response. Metastatic infections remote to the primary
colonized foci, which manifest as osteomyelitis and endo-
carditis, signify failure in local innate immunity and
therefore are characteristic manifestations by more inva-
sive serotypes. In our study, none of the patients with
bacteremic cellulitis caused by Serotype V (10/28, 36%) had
chronic skin conditions, indicating that SSTI was more likely
because of virulent factors inherent in Serotype V strains
rather than gross defects over skin or mucus, which were
prone to local infection and/or prolonged colonization. In
spite of the significant association, however, the invasive
isolates in our study were restricted to cases from a single
community, and we cannot exclude potential interference
by geographical clustering, which would be eliminated bypopulation-based active surveillance for assessing the
prevalence of GBS colonization as well as invasive
infection.
Recurrence of GBS invasive infection is not unco-
mmon.5,20,21 In most cases reported, recurrent episodes
were relapses from deep foci seeded by antecedent
bacteremia or prolonged colonizing strains because of hosts’
underlying conditions or related treatments.20 The interval
between the first and recurrent episodes was shorter if
caused by the same strain (i.e. relapse) than by different
strains (i.e. reinfection), with means of 14 and 43 weeks,
respectively.20 Relapsing episodes often manifested osteo-
myelitis or endocarditis rather than SSTI and were caused by
inadequate antimicrobial therapy for antecedent bacter-
emia. On the contrary, our recurrent cases manifested
mostly SSTI and if occurring close to the respective preceding
infections, they were caused by strains of the same sero-
variants. Given that most patients with recurrent infection
have concomitant malignancies, it is likely that impaired
host immune system may fail to generate adequate protec-
tion against reinfection by strains of identical serovariants.
Alternatively, prolonged colonization on the patients or their
house contact may increase the chance of disease relapse.
Further genome analysis of these strains should help clarify
the nature of the recurrent infection (i.e. reinfection vs.
relapse) and assist ourmanagement for preventing recurrent
infection to immunocompromised population.Acknowledgment
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